

Emiliano Calvo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9537323/publications.pdf>

Version: 2024-02-01

190
papers

10,232
citations

66343

42
h-index

38395

95
g-index

194
all docs

194
docs citations

194
times ranked

14722
citing authors

#	ARTICLE	IF	CITATIONS
1	First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 417-431.	4.2	6
2	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 499-514.	2.3	7
3	Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors. <i>Cancer Discovery</i> , 2022, 12, 1248-1265.	9.4	36
4	Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. <i>Investigational New Drugs</i> , 2022, 40, 762-772.	2.6	6
5	iRECIST and atypical patterns of response to immuno-oncology drugs. , 2022, 10, e004849.		12
6	A first-in-human phase 1 and pharmacological study of TAS-119, a novel selective Aurora A kinase inhibitor in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2021, 124, 391-398.	6.4	10
7	T-cell“engaging Therapy for Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 1595-1603.	7.0	21
8	Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 418-428.	7.0	16
9	Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody. <i>Clinical Cancer Research</i> , 2021, 27, 2168-2178.	7.0	67
10	Dosage of anti-PD-1 monoclonal antibodies: a cardinal open question. <i>Clinical and Translational Oncology</i> , 2021, 23, 1511-1519.	2.4	2
11	Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. <i>Investigational New Drugs</i> , 2021, 39, 1275-1283.	2.6	9
12	SARS-CoV-2 vaccination and phase 1 cancer clinical trials. <i>Lancet Oncology</i> , The, 2021, 22, 298-301.	10.7	11
13	Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage <sc>Colony-Stimulating</sc> Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. <i>Oncologist</i> , 2021, 26, e1508-e1513.	3.7	16
14	First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody“Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 4511-4520.	7.0	39
15	MO24-1 Phase I/IIa trial evaluating safety and clinical activity of DuoBody“PD-L1“4-1BB (GEN1046) in advanced solid tumors. <i>Annals of Oncology</i> , 2021, 32, S313.	1.2	1
16	Toxicity and antitumor activity of novel agents in elderly patients with cancer included in phase 1 studies. <i>Investigational New Drugs</i> , 2021, 39, 1694-1701.	2.6	0
17	Adoptive cell therapy for solid tumors: Chimeric antigen receptor T cells and beyond. <i>Current Opinion in Pharmacology</i> , 2021, 59, 70-84.	3.5	18
18	OC-0515 NBTXR3 activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients. <i>Radiotherapy and Oncology</i> , 2021, 161, S399.	0.6	0

#	ARTICLE	IF	CITATIONS
19	555TiP A first-in-human trial of the integrin beta-6-targeted antibody-drug conjugate, SGN-B6A, in patients with advanced solid tumors. <i>Annals of Oncology</i> , 2021, 32, S613.	1.2	1
20	540P Safety and efficacy from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating a CD8 \pm co-receptor and an affinity optimized TCR targeting MAGE-A4. <i>Annals of Oncology</i> , 2021, 32, S604-S605.	1.2	4
21	Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients. <i>Joint Bone Spine</i> , 2021, 88, 105236.	1.6	19
22	Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100405.	1.7	6
23	Doxorubicin plus lurbinedetin in patients with advanced endometrial cancer: results from an expanded phase I study. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1428-1436.	2.5	4
24	Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e392.	0.8	0
25	T cell engagers in solid tumors kick the door down. <i>Cancer Cell</i> , 2021, 39, 1461-1463.	16.8	2
26	Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. <i>Journal of Thoracic Oncology</i> , 2020, 15, 426-435.	1.1	181
27	Randomised Phase II study comparing alternating cycles of sunitinib and everolimus vs standard sequential administration in first-line metastatic renal carcinoma (SUNRISES study). <i>BJU International</i> , 2020, 126, 559-567.	2.5	5
28	Clinical Challenges of Immune Checkpoint Inhibitors. <i>Cancer Cell</i> , 2020, 38, 326-333.	16.8	286
29	Are we ready to accept intermediate outcome measures in clinical cancer trials?. <i>Annals of Oncology</i> , 2020, 31, 973-975.	1.2	1
30	Comparison of radiological criteria for hyperprogressive disease in response to immunotherapy. <i>Cancer Treatment Reviews</i> , 2020, 91, 102116.	7.7	12
31	Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial. <i>Cancers</i> , 2020, 12, 2985.	3.7	21
32	535MO BGB-A333, an anti-PD-L1 monoclonal antibody, in combination with tislelizumab in patients with urothelial carcinoma. <i>Annals of Oncology</i> , 2020, 31, S468-S469.	1.2	1
33	592P A predictive score of antitumour activity of novel agents in cancer patients treated in early phase studies. <i>Annals of Oncology</i> , 2020, 31, S497.	1.2	1
34	749P Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032. <i>Annals of Oncology</i> , 2020, 31, S582-S583.	1.2	8
35	1025MO First-in-human (FIH) phase I study of RO7122290 (RO), a novel FAP-targeted 4-1BB agonist, administered as single agent and in combination with atezolizumab (ATZ) to patients with advanced solid tumours. <i>Annals of Oncology</i> , 2020, 31, S707.	1.2	14
36	560P Safety and efficacy of Debio 1143, an antagonist of inhibitor of apoptosis proteins (IAPs), in combination with nivolumab in a phase Ib/II trial in patients (pts) failing prior PD-1/PD-L1 treatment. <i>Annals of Oncology</i> , 2020, 31, S483.	1.2	1

#	ARTICLE	IF	CITATIONS
37	587P Toxicity and antitumor activity of novel agents in elderly cancer patients in phase I studies. <i>Annals of Oncology</i> , 2020, 31, S495.	1.2	0
38	718P A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment. <i>Annals of Oncology</i> , 2020, 31, S564.	1.2	6
39	ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy. <i>ESMO Open</i> , 2020, 5, e000662.	4.5	15
40	Increased vulnerability of clinical research units during the COVID-19 crisis and their protection. <i>Cancer</i> , 2020, 126, 3907-3911.	4.1	10
41	A phase 1 study evaluating safety and pharmacokinetics of losatuxizumab vedotin (ABBV-221), an anti-EGFR antibody-drug conjugate carrying monomethyl auristatin E, in patients with solid tumors likely to overexpress EGFR. <i>Investigational New Drugs</i> , 2020, 38, 1483-1494.	2.6	15
42	Design and Conduct of Early Clinical Studies of Immunotherapy: Recommendations from the Task Force on Methodology for the Development of Innovative Cancer Therapies 2019 (MDICT). <i>Clinical Cancer Research</i> , 2020, 26, 2461-2465.	7.0	6
43	Evolving development of PD-1 therapy: Cetrelimab (JNJ-63723283) from monotherapy to combination with erdafitinib.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3055-3055.	1.6	2
44	Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVDF.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3089-3089.	1.6	3
45	OC-0560: RT-activated hafnium oxide nanoparticles in cisplatin-ineligible locally advanced HNSCC patients. <i>Radiotherapy and Oncology</i> , 2020, 152, S312.	0.6	1
46	OC-043 HNSCC in elderly frail patients treated by hafnium oxide nanoparticles activated by IMRT. <i>Radiotherapy and Oncology</i> , 2019, 132, 22-23.	0.6	0
47	Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. <i>Lancet Oncology</i> , The, 2019, 20, 1109-1123.	10.7	193
48	Updated results of the PARP1/2 inhibitor pamiparib in combination with low-dose (ld) temozolomide (TMZ) in patients (pts) with locally advanced or metastatic solid tumours. <i>Annals of Oncology</i> , 2019, 30, v166-v167.	1.2	1
49	First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumours: Dose-optimization cohorts. <i>Annals of Oncology</i> , 2019, 30, v169-v170.	1.2	1
50	Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma. <i>Annals of Oncology</i> , 2019, 30, v523-v524.	1.2	2
51	Phase I open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABBV-181 and rovalpituzumab tesirine (ROVA-T) in patients with small cell lung cancer. <i>Annals of Oncology</i> , 2019, 30, v715-v716.	1.2	1
52	Safety, tolerability and activity of autologous T-cells with enhanced T-cell receptors specific to NY ESO 1/LAGE 1a (GSK3377794) alone, or in combination with pembrolizumab, in advanced non-small cell lung cancer: A phase Ib/IIa randomised pilot study. <i>Annals of Oncology</i> , 2019, 30, v657-v658.	1.2	0
53	Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2825-2834.	1.6	280
54	Systemic phenotype of sarcoidosis associated with radiological stages. Analysis of 1230 patients. <i>European Journal of Internal Medicine</i> , 2019, 69, 77-85.	2.2	20

#	ARTICLE	IF	CITATIONS
55	A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)., 2019, 7, 20.		68
56	Early-phase clinical drug development of novel agents: a changing paradigm. <i>Annals of Oncology</i> , 2019, 30, 1033-1037.	1.2	5
57	New designs in early clinical drug development. <i>Annals of Oncology</i> , 2019, 30, 1460-1465.	1.2	14
58	Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 4888-4897.	7.0	181
59	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results. <i>Journal of Clinical Oncology</i> , 2019, 37, 1608-1616.	1.6	185
60	Modulation of Fexofenadine Pharmacokinetics by Osimertinib in Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1099-1109.	2.0	6
61	Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 3220-3228.	7.0	179
62	The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma. <i>Oncologist</i> , 2019, 24, 338-348.	3.7	34
63	First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019, 134, 3924-3924.	1.4	8
64	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	27.8	572
65	Rational Approaches for Combination Therapy Strategies Targeting the MAP Kinase Pathway in Solid Tumors. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 3-16.	4.1	81
66	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 853-861.e4.	16.8	725
67	Hepatic safety analysis of trabectedin: results of a pharmacokinetic study with trabectedin in patients with hepatic impairment and experience from a phase 3 clinical trial. <i>Investigational New Drugs</i> , 2018, 36, 476-486.	2.6	5
68	First clinical symptom as a prognostic factor in systemic sclerosis: results of a retrospective nationwide cohort study. <i>Clinical Rheumatology</i> , 2018, 37, 999-1009.	2.2	27
69	CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2836-2844.	1.6	459
70	Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1 mg/kg + ipilimumab 3 mg/kg expansion from CheckMate 032. <i>Annals of Oncology</i> , 2018, 29, viii725.	1.2	9
71	Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data. <i>Annals of Oncology</i> , 2018, 29, x25.	1.2	8
72	Efficacy and safety of pazopanib in patients with advanced and/or metastatic renal cell carcinoma (mRCC) after previous checkpoint inhibitor treatment. <i>European Urology Supplements</i> , 2018, 17, e2957.	0.1	0

#	ARTICLE	IF	CITATIONS
73	P1.12-20 Overall Survival with Lurbinectedin Plus Doxorubicin in Relapsed SCLC. Results from an Expansion Cohort of a Phase Ib Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, S581.	1.1	7
74	A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours. <i>European Journal of Cancer</i> , 2018, 104, 1-8.	2.8	10
75	Phase I/II, multicenter, open-label study of intratumoral/intralesional administration of the retinoic acid-inducible gene I (RIG-I) activator MK-4621 in patients with advanced or recurrent tumors. <i>Annals of Oncology</i> , 2018, 29, viii712.	1.2	19
76	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. <i>Annals of Oncology</i> , 2018, 29, 2175-2182.	1.2	20
77	EP-1705: Radiotherapy: a promising alternative treatment for painful osteoarticular degenerative diseases. <i>Radiotherapy and Oncology</i> , 2018, 127, S914-S915.	0.6	0
78	Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). <i>Oncologist</i> , 2018, 23, 1407-e136.	3.7	127
79	Clinical pharmacology assessment of PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in adult patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2574-2574.	1.6	2
80	PF-06647020 (PF-7020), an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients (pts) with advanced solid tumors: Results of a phase I dose escalation and expansion study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 5565-5565.	1.6	18
81	Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2018, 36, 58-58.	1.6	3
82	Nivolumab monotherapy in metastatic urothelial carcinoma: Longer-term efficacy and safety results from the CheckMate 032 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 414-414.	1.6	10
83	Clinical and pathologic features of patients with non-epithelial ovarian cancer: retrospective analysis of a single institution 15-year experience. <i>Clinical and Translational Oncology</i> , 2017, 19, 173-179.	2.4	4
84	A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. <i>BMC Cancer</i> , 2017, 17, 137.	2.6	47
85	The future of oncology therapeutics. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 563-565.	2.4	3
86	MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, S393-S394.	1.1	20
87	A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 108, 212-216.	2.0	35
88	Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study. <i>Annals of Oncology</i> , 2017, 28, 2559-2566.	1.2	80
89	Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC). <i>Annals of Oncology</i> , 2017, 28, iii151.	1.2	18
90	Somatic BRCA2 bi-allelic loss in the primary prostate cancer was associated to objective response to PARPi in a sporadic CRPC patient. <i>Annals of Oncology</i> , 2017, 28, 1158-1159.	1.2	3

#	ARTICLE	IF	CITATIONS
91	Immunotherapy-based combinations: current status and perspectives. <i>Current Opinion in Oncology</i> , 2017, 29, 382-394.	2.4	7
92	A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2017, 23, 1177-1185.	7.0	23
93	Phase I clinical and pharmacokinetic study of PM01183 (a tetrahydroisoquinoline, Lurbinectedin) in combination with gemcitabine in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017, 35, 198-206.	2.6	22
94	A Literature Review of Health Economic Assessments, Health Care Resource Utilization (HCRU), and Health Related Quality-of-Life (HRQOL) in Patients with Gastric Cancer (GC). <i>Value in Health</i> , 2017, 20, A437-A438.	0.3	0
95	Afatinib (A) plus cetuximab (C) in the treatment of patients (pts) with NSCLC: The story so far. <i>Annals of Oncology</i> , 2017, 28, ii30-ii31.	1.2	1
96	Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data. <i>Annals of Oncology</i> , 2017, 28, ii32-ii33.	1.2	10
97	Nivolumab (NIVO) in patients (pts) with advanced (adv) chemotherapy-refractory (CT-Rx) esophagogastric (EG) cancer according to microsatellite instability (MSI) status: checkmate 032. <i>Annals of Oncology</i> , 2017, 28, v229-v230.	1.2	5
98	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71.		113
99	Activity of lurbinectedin as single agent and in combination in patients with advanced small cell lung cancer (SCLC). <i>Annals of Oncology</i> , 2017, 28, v539-v540.	1.2	4
100	Real-world productivity, healthcare resource utilization (HRU), and quality of life (QOL) in patients with advanced gastric cancer (GC) in Korea and Japan. <i>Annals of Oncology</i> , 2017, 28, x60-x61.	1.2	0
101	Preliminary results from a phase 1 study of the antibody-drug conjugate ABBV-221 in patients with solid tumors likely to express EGFR.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2510-2510.	1.6	11
102	Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3002-3002.	1.6	129
103	Activity of lurbinectedin (PM01183) as single agent and in combination in patients with endometrial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 5586-5586.	1.6	5
104	Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032.. <i>Journal of Clinical Oncology</i> , 2017, 35, 8503-8503.	1.6	60
105	Interim safety and clinical activity in patients (pts) with advanced gastric or gastroesophageal junction (G/GE) adenocarcinoma from a multicohort phase 1 study of ramucirumab (R) plus pembrolizumab (P).. <i>Journal of Clinical Oncology</i> , 2017, 35, 102-102.	1.6	20
106	Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors. <i>Oncology</i> , 2016, 91, 251-260.	1.9	34
107	A phase 1 study of PF-06647020, an antibody-drug conjugate (ADC) targeting protein tyrosine kinase 7 (PTK7), in patients with advanced solid tumors including platinum resistant ovarian cancer (OVCA). <i>Annals of Oncology</i> , 2016, 27, vi570.	1.2	8
108	Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 1590-1598.	10.7	594

#	ARTICLE	IF	CITATIONS
109	Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. <i>Cancer Treatment Reviews</i> , 2016, 50, 109-117.	7.7	64
110	Effect of veliparib (ABT-888) on cardiac repolarization in patients with advanced solid tumors: a randomized, placebo-controlled crossover study. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 1003-1011.	2.3	13
111	A mechanism of action study of intra-tumoral or intravenous dosing of enadenotucirev, an oncolytic adenovirus in patients with colon, lung, bladder and renal carcinoma undergoing resection of primary tumor. <i>Annals of Oncology</i> , 2016, 27, vi372.	1.2	0
112	Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. <i>Lancet Oncology</i> , The, 2016, 17, 883-895.	10.7	1,091
113	Pharmacokinetics, metabolism, and excretion of 14C-labeled belinostat in patients with recurrent or progressive malignancies. <i>Investigational New Drugs</i> , 2016, 34, 193-201.	2.6	16
114	Safety and activity of nivolumab monotherapy in advanced and metastatic (A/M) gastric or gastroesophageal junction cancer (GC/GEC): Results from the CheckMate-032 study.. <i>Journal of Clinical Oncology</i> , 2016, 34, 6-6.	1.6	33
115	Pharmacogenomics, Pharmacokinetics, and Pharmacodynamics in the Era of Targeted Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e175-e184.	3.8	8
116	An Indirect Comparison of Everolimus Versus Axitinib in US Patients With Advanced Renal Cell Carcinoma in Whom Prior Sunitinib Therapy Failed. <i>Clinical Therapeutics</i> , 2015, 37, 2552-2559.	2.5	13
117	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1002-1009.	7.0	39
118	Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor- β 2 receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. <i>Investigational New Drugs</i> , 2015, 33, 357-370.	2.6	90
119	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2015, 33, 710-719.	2.6	24
120	First-in-Human Dose Study of the Novel Transforming Growth Factor- β 2 Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. <i>Clinical Cancer Research</i> , 2015, 21, 553-560.	7.0	199
121	Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan- α Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2015, 33, 3401-3408.	1.6	324
122	Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study. <i>Targeted Oncology</i> , 2015, 10, 111-123.	3.6	158
123	Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study. <i>British Journal of Cancer</i> , 2014, 111, 2058-2066.	6.4	31
124	Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. <i>Annals of Oncology</i> , 2014, 25, 763-773.	1.2	67
125	Controversies in renal cell carcinoma: Treatment choice after progression on vascular endothelial growth factor-targeted therapy. <i>European Journal of Cancer</i> , 2014, 50, 1321-1329.	2.8	31
126	Phase I study of carboplatin in combination with PM00104 (Zalypsis $\text{\textcircled{R}}$) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 644-652.	2.6	1

#	ARTICLE	IF	CITATIONS
127	Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer. <i>Investigational New Drugs</i> , 2014, 32, 955-968.	2.6	55
128	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS</i> and <i>RAF</i> Mutations. <i>Clinical Cancer Research</i> , 2014, 20, 4251-4261.	7.0	60
129	New approach to cancer therapy based on a molecularly defined cancer classification. <i>Ca-A Cancer Journal for Clinicians</i> , 2014, 64, 70-74.	329.8	22
130	A Phase 1 Study of Enadenotucirev, an Oncolytic Ad11/Ad3 Chimeric Group B Adenovirus, Administered Intravenously - Analysis of Dose Expansion and Repeat Cycle Cohorts in Patients with Metastatic Colorectal Cancer (McrC). <i>Annals of Oncology</i> , 2014, 25, iv367.	1.2	7
131	A first-in-class, first-in-human phase I study of enadenotucirev, an oncolytic Ad11/Ad3 chimeric group B adenovirus, administered intravenously in patients with metastatic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3103-3103.	1.6	12
132	What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?. <i>Cancer Treatment Reviews</i> , 2013, 39, 366-374.	7.7	29
133	Simultaneous online SPE-HPLC-MS/MS analysis of docetaxel, temsirolimus and sirolimus in whole blood and human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 921-922, 35-42.	2.3	34
134	Phase II study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. <i>European Journal of Cancer</i> , 2013, 49, 1815-1824.	2.8	18
135	Reply to A. Ocana et al. <i>Journal of Clinical Oncology</i> , 2013, 31, 1253-1254.	1.6	0
136	Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. <i>Journal of Clinical Oncology</i> , 2012, 30, e45-e48.	1.6	79
137	Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. <i>British Journal of Cancer</i> , 2012, 106, 1475-1480.	6.4	26
138	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. <i>Journal of Clinical Oncology</i> , 2012, 30, 3444-3447.	1.6	18
139	Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy. <i>Annals of Oncology</i> , 2012, 23, 1241-1249.	1.2	51
140	Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. <i>European Journal of Cancer</i> , 2012, 48, 333-339.	2.8	117
141	Phase I dose-escalation study of vinflunine hard capsules administered twice a day for 2 consecutive days every week in patients with advanced/metastatic solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 1467-1475.	2.3	4
142	Efficacy and Safety of Everolimus in Elderly Patients With Metastatic Renal Cell Carcinoma: An Exploratory Analysis of the Outcomes of Elderly Patients in the RECORD-1 Trial. <i>European Urology</i> , 2012, 61, 826-833.	1.9	59
143	Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma. <i>Anticancer Research</i> , 2012, 32, 2399-406.	1.1	9
144	Non-clear cell advanced kidney cancer. <i>Anti-Cancer Drugs</i> , 2011, 22, S9-S14.	1.4	12

#	ARTICLE	IF	CITATIONS
145	Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. <i>Clinical and Translational Oncology</i> , 2011, 13, 869-877.	2.4	15
146	A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 6304-6312.	7.0	113
147	Phase I study of PM00104 in combination with carboplatin (C) in patients (pts) with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2011, 29, e13085-e13085.	1.6	1
148	Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 1-10.	5.9	3
149	Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: focus on special populations. <i>Cancer and Metastasis Reviews</i> , 2010, 29, 11-20.	5.9	3
150	Noninfectious Pneumonitis after Everolimus Therapy for Advanced Renal Cell Carcinoma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 182, 396-403.	5.6	202
151	Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 2010, 11, 350-357.	10.7	64
152	Multiple roles and therapeutic implications of Akt signaling in cancer. <i>OncoTargets and Therapy</i> , 2009, 2, 135.	2.0	14
153	Satraplatin, an Oral Platinum, Administered on a Five-day Every-Five-Week Schedule: a Pharmacokinetic and Food Effect Study. <i>Clinical Cancer Research</i> , 2009, 15, 3866-3871.	7.0	15
154	Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1065-1071.	2.3	14
155	Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1-13.	2.3	10
156	A Phase I Dose-Escalation Study of SR271425, an Intravenously Dosed Thioxanthone Analog, Administered Weekly in Patients With Refractory Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 9-14.	1.3	10
157	Acute severe hypothyroidism induced by sunitinib. <i>Radiotherapy and Oncology</i> , 2008, 89, 124-125.	0.6	2
158	Dose- and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus: A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 1603-1610.	1.6	519
159	Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer. <i>Annals of Oncology</i> , 2007, 18, 761-767.	1.2	28
160	Analysis of CXCL12 3'UTR G>A polymorphism in colorectal cancer. <i>Oncology Reports</i> , 2007, 18, 1583-7.	2.6	20
161	Ethnic Differences in Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. <i>Journal of Clinical Oncology</i> , 2006, 24, 2158-2163.	1.6	143
162	Molecular biology of testicular germ cell tumors. <i>Clinical and Translational Oncology</i> , 2006, 8, 846-850.	2.4	6

#	ARTICLE	IF	CITATIONS
163	Novel Agents That Target Tublin and Related Elements. <i>Seminars in Oncology</i> , 2006, 33, 421-435.	2.2	64
164	Clinical experience with monoclonal antibodies to epidermal growth factor receptor. <i>Current Oncology Reports</i> , 2005, 7, 96-103.	4.0	21
165	Approaches to optimize the use of monoclonal antibodies to epidermal growth factor receptor. <i>Current Oncology Reports</i> , 2005, 7, 123-128.	4.0	3
166	Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Espa�ol de Investigaci�n en C�ncer de Ovario) study. <i>Annals of Oncology</i> , 2005, 16, 749-755.	1.2	106
167	Role of von Willebrand factor levels in the prognosis of stage IV colorectal cancer: Do we have enough evidence?. <i>World Journal of Gastroenterology</i> , 2005, 11, 6072.	3.3	3
168	Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule. <i>Clinical Cancer Research</i> , 2004, 10, 7112-7120.	7.0	76
169	Effect of Epidermal Growth Factor Receptor Mutations on the Response to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Target-Based Populations for Target-Based Drugs. <i>Clinical Lung Cancer</i> , 2004, 6, S35-S42.	2.6	8
170	Perfusi�n de extremidad aislada en sarcomas de partes blandas irresecables: un nuevo est�ndar. <i>Revista Espa�ola De Cirug�a Ortop�dica Y Traumatolog�a</i> , 2004, 48, 57-64.	0.1	1
171	Reproductive performance of lactating dairy cows treated with cloprostenol at the time of insemination. <i>Theriogenology</i> , 2004, 62, 677-689.	2.1	32
172	Paclitaxel, Cisplatin, and Vinorelbine Combination Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2004, 27, 299-303.	1.3	4
173	Hepatic artery chemotherapy and colorectal liver metastases. <i>Lancet, The</i> , 2003, 361, 1743.	13.7	0
174	Comparative lactogenic antibody responses of cattle from European field trials with a new enteric disease vaccine. <i>Veterinary Record</i> , 2003, 152, 751-752.	0.3	6
175	Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer. <i>Oncology</i> , 2003, 64, 28-35.	1.9	126
176	Comparison of unidimensional and bidimensional measurements in metastatic non-small cell lung cancer. <i>British Journal of Cancer</i> , 2002, 87, 158-160.	6.4	21
177	Cervical Phrenic Nerve Block for Intractable Hiccups in Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2002, 94, 1175-1176.	6.3	24
178	Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer. <i>Oncology</i> , 2002, 63, 254-265.	1.9	21
179	Systemic Chemotherapy for Metastatic Colorectal Cancer: Reasons to Combine. <i>Clinical Colorectal Cancer</i> , 2002, 2, 170-172.	2.3	3
180	Irinotecan, Oxaliplatin, and 5-Fluorouracil/Leucovorin Combination Chemotherapy in Advanced Colorectal Carcinoma: A Phase II Study. <i>Clinical Colorectal Cancer</i> , 2002, 2, 104-110.	2.3	35

#	ARTICLE	IF	CITATIONS
181	Docetaxel Plus Vinorelbine as Salvage Chemotherapy in Advanced Breast Cancer: A Phase II Study. <i>Breast Cancer Research and Treatment</i> , 2002, 76, 47-56.	2.5	17
182	Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma. <i>Cancer</i> , 2001, 92, 2435-2443.	4.1	16
183	Adjuvant Chemotherapy for Completely Resected Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2001, 344, 689-690.	27.0	2
184	Differences in the <i>Candida albicans</i> antigenic expression after heat shock and infection. <i>Revista Iberoamericana De Micologia</i> , 2001, 18, 6-11.	0.9	2
185	Enteric plexus and interstitial cells of Cajal: interrelationship in the stomach of <i>Podarcis hispanica</i> (Reptilia). An ultrastructural study. <i>Histology and Histopathology</i> , 2001, 16, 869-81.	0.7	7
186	Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma. <i>Cancer</i> , 2000, 89, 2622-2629.	4.1	11
187	Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. <i>Biomedical Applications</i> , 2000, 740, 159-168.	1.7	52
188	Simple and sensitive determination of 5-fluorouracil in plasma by high-performance liquid chromatography. <i>Biomedical Applications</i> , 1999, 736, 97-102.	1.7	23
189	Haemoglobin-fortified cereal: an alternative weaning food with high iron bioavailability. <i>European Journal of Clinical Nutrition</i> , 1989, 43, 237-43.	2.9	10
190	Nutritional significance of interactions between iron and food components. <i>Archivos Latinoamericanos De Nutricion</i> , 1983, 33, 33-41.	0.3	4